Cargando…
The Effect of Third Dose of Pfizer/BioNTech and Moderna COVID-19 mRNA Vaccines on IgG Antibody Titers
With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, the Centers for Disease Control and Prevention (CDC) authorized the third dose of the Pfizer-BioNTech (BNT162b2) vaccine with the rationale for prolonged elevation of anti-SARS-CoV-2 antibody titers and prot...
Autores principales: | Khuc, Thao A, Pequeno, Gregery, Betancourt-Garcia, Monica, Casciato, Adrienne M, Gomez-Martinez, Marissa, Arroyo, Carlos D, Pope, Bill D, Narmala, Shravan, Rao, Sohail |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413993/ https://www.ncbi.nlm.nih.gov/pubmed/37575726 http://dx.doi.org/10.7759/cureus.41696 |
Ejemplares similares
-
Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
Publicado: (2021) -
Overt Hypothyroidism Status Post Pfizer-BioNTech Vaccination: A Case Study
por: Nandennagari, Sailaja, et al.
Publicado: (2023) -
Anaphylaxis to Pfizer/BioNTech mRNA COVID-19 Vaccine in a Patient With Clinically Confirmed PEG Allergy
por: McSweeney, Morgan D., et al.
Publicado: (2021) -
Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022) -
Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
por: Alqassieh, Rami, et al.
Publicado: (2021)